{
    "root": "3001938f-8a0f-6a33-e063-6294a90ab498",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "CYCLOPHOSPHAMIDE",
    "value": "20250310",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "MONOTHIOGLYCEROL",
            "code": "AAO1P0WSXJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_74537"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09152"
        },
        {
            "name": "CYCLOPHOSPHAMIDE ANHYDROUS",
            "code": "6UXW23996M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ],
    "indications": {
        "text": "cyclophosphamide alkylating indicated treatment : malignant diseases : malignant lymphomas : hodgkin 's disease , lymphocytic lymphoma , mixed-cell type lymphoma , histiocytic lymphoma , burkitt 's lymphoma ; multiple myeloma , leukemias , mycosis fungoides , neuroblastoma , adenocarcinoma ovary , retinoblastoma , breast carcinoma . ( 1.1 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "lymphoma (DOID:0060058)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060058"
            },
            {
                "text": "histiocytic lymphoma (DOID:8538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8538"
            },
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "mycosis (DOID:1564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1564"
            },
            {
                "text": "mycosis fungoides (DOID:8691)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8691"
            },
            {
                "text": "neuroblastoma (DOID:769)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_769"
            },
            {
                "text": "adenocarcinoma (DOID:299)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_299"
            },
            {
                "text": "retinoblastoma (DOID:768)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_768"
            },
            {
                "text": "breast carcinoma (DOID:3459)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3459"
            },
            {
                "text": "carcinoma (DOID:305)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_305"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "immediately , adequate amounts fluid ingested infused force diuresis order reduce risk urinary tract toxicity . therefore , cyclophosphamide administered morning .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "cyclophosphamide injection 200 mg/ml sterile clear colorless solution ready-to-dilute solution containing cyclophosphamide , usp . cyclophosphamide injection ndc number strength vial presentation 51407-748-02 500 mg/2.5 ml multiple-dose vial , carton 1 51407-749-05 1 g/5 ml multiple-dose vial , carton 1 51407-750-10 2 g/10 ml multiple-dose vial , carton 1 store vials refrigerated 2\u00b0c 8\u00b0c ( 36\u00b0f 46\u00b0f ) . store diluted solutions cyclophosphamide according table 1 [ ( 2.3 ) ] cyclophosphamide antineoplastic product . follow special handling disposal procedures 1 .",
    "adverseReactions": "hypersensitivity cyclophosphamide contraindicated patients history severe hypersensitivity , metabolites , components product . anaphylactic including death reported cyclophosphamide . possible cross-sensitivity alkylating agents occur . urinary outflow obstruction cyclophosphamide contraindicated patients urinary outflow obstruction [ ( 5.2 ) ] .",
    "indications_original": "Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 )",
    "contraindications_original": "During or immediately after the administration, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide should be administered in the morning.",
    "warningsAndPrecautions_original": "Cyclophosphamide Injection is a 200 mg/mL sterile clear colorless solution ready-to-dilute solution containing cyclophosphamide, USP.\n                  Cyclophosphamide Injection\n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              NDC Number\n                           \n                           \n                              Strength\n                           \n                           \n                              Vial Presentation\n                           \n                        \n                        \n                           51407-748-02\n                           500 mg/2.5 mL                          \n                           Multiple-Dose Vial, carton of 1\n                        \n                        \n                           51407-749-05\n                           1 g/5 mL\n                           Multiple-Dose Vial, carton of 1\n                        \n                        \n                           51407-750-10\n                           2 g/10 mL\n                           Multiple-Dose Vial, carton of 1\n                        \n                     \n                  \n                  Store the vials refrigerated at 2\u00b0C to 8\u00b0C (36\u00b0F to 46\u00b0F).\n                  Store diluted solutions of cyclophosphamide according to Table 1 \n  [see \n   Dosage and Administration (2.3)] \n  \n                  \n                  Cyclophosphamide is an antineoplastic product. Follow special handling and disposal procedures \n  1.",
    "adverseReactions_original": "Hypersensitivity\n                  \n                  Cyclophosphamide is contraindicated in patients who have a history of severe hypersensitivity reactions to it, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur.\n                  \n                     Urinary Outflow Obstruction\n                  \n                  Cyclophosphamide is contraindicated in patients with urinary outflow obstruction\n \n  [see\n  \n   Warnings and Precautions (5.2)].",
    "drug": [
        {
            "name": "CYCLOPHOSPHAMIDE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4027"
        }
    ]
}